Market Closed -
London S.E.
11:35:20 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
1.9
GBX
|
-6.86%
|
|
-11.21%
|
+13.98%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
225.3
|
16.39
|
26.78
|
33.4
|
16.51
|
6.135
|
Enterprise Value (EV)
1 |
222.8
|
11.6
|
25.44
|
28.18
|
14.87
|
5.467
|
P/E ratio
|
-35.8
x
|
-2.26
x
|
-4.01
x
|
-3.89
x
|
-2.03
x
|
-1.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,497
x
|
202
x
|
344
x
|
264
x
|
140
x
|
-
|
EV / Revenue
|
1,481
x
|
143
x
|
326
x
|
223
x
|
126
x
|
-
|
EV / EBITDA
|
-31.4
x
|
-1.46
x
|
-4.11
x
|
-5.2
x
|
-2.95
x
|
-1.88
x
|
EV / FCF
|
-218
x
|
-4.22
x
|
-7.29
x
|
-19
x
|
-8.31
x
|
-2.99
x
|
FCF Yield
|
-0.46%
|
-23.7%
|
-13.7%
|
-5.26%
|
-12%
|
-33.5%
|
Price to Book
|
63
x
|
2.15
x
|
5.08
x
|
3.46
x
|
4.26
x
|
2.43
x
|
Nbr of stocks (in thousands)
|
132,523
|
139,467
|
167,361
|
250,221
|
250,221
|
333,403
|
Reference price
2 |
1.700
|
0.1175
|
0.1600
|
0.1335
|
0.0660
|
0.0184
|
Announcement Date
|
18-05-25
|
19-06-03
|
20-04-30
|
21-04-29
|
22-05-24
|
23-06-06
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.1505
|
0.0813
|
0.0779
|
0.1267
|
0.1184
|
-
|
EBITDA
1 |
-7.096
|
-7.947
|
-6.194
|
-5.418
|
-5.046
|
-2.911
|
EBIT
1 |
-7.234
|
-8.08
|
-6.282
|
-5.589
|
-5.16
|
-3.029
|
Operating Margin
|
-4,807.88%
|
-9,941.04%
|
-8,061.14%
|
-4,412.7%
|
-4,359.84%
|
-
|
Earnings before Tax (EBT)
1 |
-6.997
|
-7.955
|
-6.744
|
-7.246
|
-8.941
|
-4.456
|
Net income
1 |
-6.223
|
-7.207
|
-6.124
|
-6.86
|
-8.174
|
-3.807
|
Net margin
|
-4,136.06%
|
-8,866.22%
|
-7,858.31%
|
-5,415.72%
|
-6,906.55%
|
-
|
EPS
2 |
-0.0475
|
-0.0519
|
-0.0399
|
-0.0343
|
-0.0325
|
-0.0126
|
Free Cash Flow
1 |
-1.021
|
-2.747
|
-3.491
|
-1.483
|
-1.79
|
-1.83
|
FCF margin
|
-678.79%
|
-3,379.38%
|
-4,479.68%
|
-1,171.12%
|
-1,512.14%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18-05-25
|
19-06-03
|
20-04-30
|
21-04-29
|
22-05-24
|
23-06-06
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2.47
|
4.79
|
1.34
|
5.22
|
1.65
|
0.67
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.02
|
-2.75
|
-3.49
|
-1.48
|
-1.79
|
-1.83
|
ROE (net income / shareholders' equity)
|
-136%
|
-129%
|
-95%
|
-91.9%
|
-116%
|
-110%
|
ROA (Net income/ Total Assets)
|
-77.1%
|
-73.9%
|
-54.3%
|
-41.8%
|
-38.1%
|
-38%
|
Assets
1 |
8.071
|
9.757
|
11.28
|
16.41
|
21.43
|
10.03
|
Book Value Per Share
2 |
0.0300
|
0.0500
|
0.0300
|
0.0400
|
0.0200
|
0.0100
|
Cash Flow per Share
2 |
0.0200
|
0.0400
|
0.0100
|
0.0200
|
0.0100
|
0
|
Capex
1 |
0.03
|
0.1
|
0.11
|
0.36
|
0.05
|
0.11
|
Capex / Sales
|
16.94%
|
126.57%
|
137.45%
|
284.44%
|
43.04%
|
-
|
Announcement Date
|
18-05-25
|
19-06-03
|
20-04-30
|
21-04-29
|
22-05-24
|
23-06-06
|
|
1st Jan change
|
Capi.
|
---|
| +13.98% | 9.93M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|